secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2023-09-20T23:59:59+00:00
Accession:  0001193125-23-238588
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences annual meeting: two directors elected, say-on-pay fails, equity plan approved
--------------------------------------------------------------------------------

- Preliminary vote shows Eichenfield (16.4M for) and Wagner (16.8M for) elected; McIntyre and Hacke not elected.
- Advisory vote on executive compensation failed: 9.9M for vs 11.8M against; abstentions 5.8M.
- Amended 2021 Equity Incentive Plan approved: 16.8M for, 8.5M against, 2.1M abstentions.
- Shareholder proposals to amend bylaws and remove preferred stock rights both defeated.
- Ratification of auditor Mayer Hoffman McCann passed with 17.3M for; results subject to final certification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/d538582d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-238588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer